Breakthrough in 3D-Bioprinted Tissue and Organ Technology Following Positive Animal Trials
April 08, 2025 – Berlin, Germany
Cellbricks, a regenerative medicine company developing scalable solutions for human tissue and organ replacement using 3D-bioprinting, has achieved a significant milestone with positive in vivo results from its preclinical studies. Seven weeks after implanting its bioprinted adipose tissue into mice, the grafts showed full tissue integration, vascular formation, and no fibrosis. These results represent the first commercial demonstration of seamless host tissue integration using a bioprinted adipose tissue graft – and mark a critical step toward clinical translation.
Founded in 2016 with the mission to bring 3D-bioprinting into hospitals and offer a solution to organ shortage, Cellbricks aims to develop implantable, immune-compatible human tissue that restores vital tissue and organ function. The company’s platform is built on proprietary 3D-bioprinting technology and has demonstrated promising results across several bioprinted tissue types, including adipose tissue and liver tissue.
„We have seen rapid vascular formation, no fibrosis, and full tissue integration in our adipose tissue grafts – a significant milestone in the validation of our platform and the development of new therapeutic approaches to bring new hope to patients,“ said Dr. Kattayoun Kordy, Chief Medical Officer at Cellbricks. „The potential to bioprint viable, functional living tissue is becoming very real“.
A Pipeline with Multi-Billion-Dollar Market Potential
The company is taking a staged approach to clinical translation, with its most advanced program focused on wound healing – an area with well-defined indications and a clear regulatory pathway.
Cellbricks’ most advanced program focuses on adipose tissue to fill deep wounds. Derived from the patient’s own cells, the graft integrates seamlessly with the host tissue, promotes vascularisation and supports rapid healing, bringing a novel therapeutic approach to the USD 60 billion wound care market. Preclinical studies in mice have demonstrated high cell viability, rapid vascularisation and stable tissue integration without fibrosis.
In parallel, Cellbricks is advancing the development of implantable, metabolically active liver tissue with the potential to function without lifelong immunosuppression. Designed to restore liver function, the graft is intended to serve as a bridge to transplantation – with the long-term goal of enabling full liver replacement. This approach targets the global chronic liver disease market, valued at USD 38.6 billion. The company has already demonstrated sustained metabolic activity in its bioengineered liver tissue over several weeks, with further in vivo development underway.
Road to FDA Approval, Mission & Future Growth
„Our vision is clear: a future where tissue and organ failure is no longer a life- threatening, irreversible condition, thanks to an unlimited supply of readily available, biofabricated tissues and organs that do not require immunosuppressive drugs. Our promising in vivo results bring us one step closer to making this vision a reality,“ said Alexander Leutner.
About Cellbricks Therapeutics
Cellbricks Therapeutics is a Berlin-based biotech company pioneering the future of regenerative medicine and longevity. Built on deeptech innovation, the company combines proprietary 3D-bioprinting technology with advanced biomaterials and human cells to develop implantable tissue grafts for clinical use. Cellbricks’ mission is to transform healthcare by restoring organ function and replacing damaged tissue with living, functional implants – produced reliably and at scale.
